北交所新股申购报告：普昂医疗：输注穿刺器械小巨人全球市占率Top3，胰岛素笔针+微创介入双轮驱动

Company Investment Rating - The report does not explicitly state an investment rating for the company. Core Insights - Puang Medical is recognized as a national-level specialized and innovative "little giant" enterprise, focusing on diabetes care, general drug infusion, and minimally invasive interventional medical devices. The company has a strong market position in insulin pen needles, which accounted for 65.80% of its revenue in the first half of 2025. The company achieved total revenue of 318 million yuan in 2024, representing a year-on-year growth of 34.61%, with a net profit of 64.88 million yuan, up 41.34% year-on-year. The gross margin and net margin for 2024 were 49.44% and 20.38%, respectively [1][3][18]. Company Overview - Puang Medical specializes in diabetes care, general drug infusion, and minimally invasive interventional medical devices. The company has developed a comprehensive product matrix targeting chronic diseases such as diabetes, tumors, and gastrointestinal diseases. The company emphasizes innovation and has received numerous awards for its technological advancements [13][18]. - The company's main revenue source is diabetes care products, which accounted for 82.47% of total revenue in 2024. The insulin pen needle is the core product, with significant market share and continuous product innovation [18][20]. Financial Performance - In 2024, the revenue from diabetes care products reached 263 million yuan, a year-on-year increase of 29.62%. The gross margin for these products improved from 48.28% in 2022 to 51.40% in 2024, with further increases expected in 2025 [28][29]. - The general drug infusion segment generated revenue of 40.75 million yuan in 2024, reflecting a year-on-year growth of 47.41% [41][45]. Industry Insights - The global medical device market is projected to grow from 566.2 billion USD in 2023 to 772.5 billion USD by 2029. The Chinese market for low-value medical consumables is expected to reach 128 billion yuan, with infusion and puncture devices being the largest segment [2]. - The insulin pen needle market is expected to grow from 1.35 billion USD in 2024 to 1.99 billion USD by 2031, with a CAGR of 5.8%. The diabetes prevalence is also on the rise, with an estimated 7.83 billion adults affected by 2045 [2][3]. Competitive Position - Puang Medical holds a global market share of 11.78% in insulin pen needles, ranking second globally, with significant shares in Europe (23.69%) and China (9.74%) [3][12]. - The company has a strong patent portfolio with 116 domestic patents and 5 international patents, along with numerous certifications from CE and FDA, enhancing its competitive edge [3][12].